Seeking Alpha

Emerging Growth's  Instablog

Emerging Growth
Send Message
Founded in 2003, StockPromoters.com has tracked hundreds of thousands of promotions by thousands of promoters and counting. Stock Promotion can be an effective and necessary tool if done correctly and responsibly, and it can be crippling to both the public company and the promoter if done... More
My company:
StockPromoters.com
My blog:
StockPromoters.com
  • Three Healthcare Stocks To Watch In March 2 comments
    Mar 6, 2013 7:25 AM | about stocks: RPRX, AUXL, NBIX

    Health is wealth and, as the Dali Lama said, quite a number of men sacrifice their health to gain wealth, only to sacrifice the wealth in order to recuperate their health. However, for those of us that invest in healthcare stocks, it is quite clear that we need not sacrifice our health; we just need to peek in our portfolios. If you are planning on adding to your portfolio this month, you may want to consider the three emerging growth healthcare stocks mentioned in this article.

    The first healthcare stock is Repros Therapeutics Inc (NASDAQ: RPRX), a $203 million market cap developer of products and services geared towards reproductive health. Repros Therapeutics is qualified to be on the list because of three remarkable events in the news. The first event is that Repros Therapeutics garnered FDA approval for its testosterone drug study. The drug, called Androxal has the potential to provide a treatment for normalizing the testosterone and luteinizing hormone levels in men. The FDA has also consented to a Type B meeting for a discussion on the Phase 3 development of Proellex. Proellex is being developed by Repros as a drug for treating uterine fibroids. And finally, the FDA has approved Repros' plan for the enrolment of more patients in the study of another drug code-named ZA-302 that is being developed. Repros holds at least three new products in its development line and investors would do well to anticipate the volume of revenue that such drugs can generate when they are finally approved.

    The second healthcare stock to own in March is Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a healthcare stock with a market cap of $865 million. Auxilium Pharmaceuticals is on this list because of the strength of the financials it released in its quarterly earnings results, which saw it beating expectations by $0.11 EPS. Auxillium posted revenue of $172.50 million for the quarter over the consensus analysts' estimate of $171.20 million. Moreover, Auxillium posted a yearly revenue increase of 135.3 percent.

    The third small cap on our emerging growth healthcare list is Neurocrine Biosciences, Inc. (NASDAQ: NBIX) with its $727M market cap. Neurocrine Biosciences is focused on the development of drugs for treating immune systems and nervous disorders. Based on a new report by Global Industry Analysts, the global market for CNS Therapeutics will reach some $133 billion by 2018. As a result, there is no doubt that Neurocrine may record a level of unprecedented growth in its annals sooner than you think.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Themes: healthcare Stocks: RPRX, AUXL, NBIX
Back To Emerging Growth's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • equityvaluation
    , contributor
    Comments (11) | Send Message
     
    Merrill, which has a Buy on the stock sees significant upside in AUXL's stock price, "we believe that Dupuytren's and
    Peyronie's represent large market opportunities with
    limited competition. We also like that Xiaflex is a
    biologic, which will reduce generic risk exposure
    and improve long-term revenue and earnings
    visibility. We note the potential for value-added
    business development activity". UBS is even more bullish on AUXL, they see significant appreciation in share price and have a price target of $52!
    6 Mar 2013, 08:57 AM Reply Like
  • kelvinjohn
    , contributor
    Comment (1) | Send Message
     
    Very informative three healthcare stocks to watch in march and though the march has ended but will be of great help for coming march so bookmarked the link to share with others also.
    chiropractic libertyville il
    18 Sep 2013, 02:32 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.